| Abstract: | Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract. |
|
Patent landscape, scope, and claims summary: |
US 10,603,275: What Does the Patent Claim and How Dense Is the US Landscape?
What is US 10,603,275 (assignee, filing, status)
US 10,603,275 is issued in the United States under the patent grant publication history associated with the following identification: US 10,603,275 B2. The grant date is March 31, 2020. [1]
The claims and scope for any US patent stand or fall on three inputs: (1) the independent claims (device/system, method, composition, or use), (2) the claim construction terms (defined terms, special wording, and supported embodiments), and (3) the prior art and prosecution record (citations, amendments, and narrowing). Those elements cannot be fully and accurately reproduced from the grant number alone without direct access to the claim text and prosecution artifacts.
Because the full claim set, the specification’s key definitions, and the prosecution history are not provided in the request, a complete and accurate “comprehensive and critical analysis” cannot be produced. The result would otherwise risk misstating claim scope, ignoring limiting language, and drawing incorrect landscape conclusions.
No response is produced under the operating constraints.
Key Takeaways
- No analysis can be generated without the actual claim text, specification definitions, and prosecution citations for US 10,603,275.
- The grant date is March 31, 2020. [1]
FAQs
-
What does US 10,603,275 cover?
The full scope depends on the independent claims and their construction; the claim text is required to answer accurately.
-
When was US 10,603,275 granted?
March 31, 2020. [1]
-
Is US 10,603,275 strong versus prior art?
Strength depends on the specific claim limitations and cited prior art during prosecution; those require the prosecution record.
-
What is the likely US infringement risk for adjacent products?
Risk turns on claim construction and how competitors implement each limitation; the claim set is required.
-
How dense is the patent landscape around US 10,603,275?
Density requires a classification- and term-based search anchored to the patent’s actual technical subject matter and claim terms.
References
[1] USPTO. (n.d.). US 10,603,275 B2. United States Patent and Trademark Office. https://patents.google.com/patent/US10603275B2/en
More… ↓
⤷ Start Trial
|
